ARCHIVES

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

Porter Softens Proposal To require SBIR Scores To Match R01s

July 26, 1996

FDA Concerned About Data-Dredging In Drug-Diagnostic Applications

January 30, 2009

In Congress: Senate Committee Approves 15% Increase For NCI In FY 1999; Report Urges NCI To Increase Research In Several Cancers

September 11, 1998

Contracts Cutback Canceled 7 RFPs

August 8, 1980

Data Falsification Charge To Be Aired

June 27, 1980

DRCCA Board Oks Noncompetitive Contract Concepts

November 11, 1983